The healthcare of tomorrow Boehringer Ingelheim relies on digital transformation.
ENPNewswire-June 12, 2019--The healthcare of tomorrow Boehringer Ingelheim relies on digital transformation
(C)2019 ENPublishing - http://www.enpublishing.co.uk
Release date- 11062019 - Ingelheim - Digitalization is changing the healthcare system: Digital technologies are opening up new opportunities in the development of innovative medications and the healthcare solutions of tomorrow.
Boehringer Ingelheim uses innovative digital technologies along the entire pharmaceutical value chain with the primary goal of creating true added value for the health of humans and animals.
A wide range of initiatives for developing innovative technologies
'We are using artificial intelligence, robotics, big data, and many other digital technologies in order to accelerate the development of medications now and to improve the prevention and early detection of illnesses in the future,' says Michael Schmelmer, member of the Boehringer Ingelheim Board of Managing Directors. This is evident in a wide variety of initiatives in the field of digital healthcare solutions that Boehringer Ingelheim is pursuing in collaboration with startups and other drivers of innovation. In this way, the family-owned company is selectively supplementing its in-house expertise with external collaborations in research and development, production, and patient care.
Digital health at the re: publica digital conference
Under the heading 'Digital Transformation - Opportunities for Tomorrow's Health,' Michael Schmelmer presented some of Boehringer Ingelheim digital health projects to an attentive audience at re:publica, one of the world's premier digital conferences, which this year was held in Berlin. He emphasized that Germany currently has a great need for specialists in this field: 'As a result of the rapid digital transformation, we increasingly need digital experts, physicians, and pharmacists who want to contribute their know-how at the interface of digital technology and medicine,' said Schmelmer.
In pharmaceutical research, for example, the smart research assistant ADAM is already making use of learning algorithms to investigate new medications: 'Artificial intelligence lets us work almost twice as fast to identify molecular compounds for potential new drug substances. Medications can then be developed from them more quickly in the course of further research,' Schmelmer explains. This innovative technology thereby creates genuine added value for health: 'Most of all, it benefits...
To continue reading
Request your trial